teaser
↓Article continues below this sponsored advert↓
↑Advertisement↑
It is normally a sign of bad news but Genmab says it is delighted that Merck KGaA has returned the rights to a new lymphoma drug to the Denmark-based drugmaker.
Genmab has regained all rights to the HuMax-CD4
